06/17/13 - 09:57 AM EDT
Medivation now has a formidable competitor for prostate cancer therapy.
06/10/13 - 07:00 AM EDT
Drugs from Gilead Sciences and Roche stood out at ASCO this year, while Infinity's drug lagged.
06/06/13 - 08:00 AM EDT
Aveo's next chance to resurrect its flailing cancer drug will come in 2014/2015 with breast cancer study data.